Literature DB >> 16361646

Bone loss with exemestane: Is the jury still out?

Angela M Cheung, George Tomlinson, Paul E Goss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16361646     DOI： 10.1200/JCO.2005.04.1376

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Authors:  Landry K Kamdem; Jingyue Xi; Brandi L Clark; Bryana J Gregory; Kelley M Kidwell; Ana-Maria Storniolo; Vered Stearns; Daniel F Hayes; Christina L Gersch; James M Rae; N Lynn Henry; Daniel L Hertz
Journal:  Breast Cancer Res Treat       Date:  2019-02-12       Impact factor: 4.872

2.  Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.

Authors:  B J Gregory; S M Chen; M A Murphy; D H Atchley; L K Kamdem
Journal:  J Clin Pharm Ther       Date:  2017-07-29       Impact factor: 2.512

3.  Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.

Authors:  Shanly M Chen; Daniel H Atchley; Michael A Murphy; Bill J Gurley; Landry K Kamdem
Journal:  J Clin Pharmacol       Date:  2015-12-31       Impact factor: 3.126

4.  Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.

Authors:  Paul E Goss; Peyman Hadji; Milayna Subar; Paula Abreu; Torben Thomsen; Jose Banke-Bochita
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.